Share-based Payment Arrangement, Expense of VYNE Therapeutics Inc. from 31 Dec 2015 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
VYNE Therapeutics Inc. annual and quarterly Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2015 to 31 Dec 2025.
  • VYNE Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2025 was $529,000, a 40% decline year-over-year.
  • VYNE Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2025 was $2,725,000, a 21% decline year-over-year.
  • VYNE Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2025 was $2,308,000, a 30% decline from 2024.
  • VYNE Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $3,303,000, a 0.06% decline from 2023.
  • VYNE Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3,305,000, a 23% decline from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)

VYNE Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $2,308,000 -$995,000 -30% 01 Jan 2025 31 Dec 2025 10-K 27 Feb 2026 2025 FY
2024 $3,303,000 -$2,000 -0.06% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2026 2025 FY
2023 $3,305,000 -$992,000 -23% 01 Jan 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
2022 $4,297,000 -$3,783,000 -47% 01 Jan 2022 31 Dec 2022 10-K 01 Mar 2024 2023 FY
2021 $8,080,000 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
2019 $6,701,000 +$6,001,000 +857% 01 Jan 2019 31 Dec 2019 10-K 03 Mar 2020 2019 FY
2018 $700,000 -$752,000 -52% 01 Jan 2018 31 Dec 2018 10-K 04 Mar 2021 2020 FY
2017 $1,452,000 +$879,000 +153% 01 Jan 2017 31 Dec 2017 10-K 03 Mar 2020 2019 FY
2016 $573,000 +$508,000 +782% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
2015 $65,000 01 Jan 2015 31 Dec 2015 10-K 28 Mar 2018 2017 FY

VYNE Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $2,725,000 $529,000 -$356,000 -40% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $3,081,000 $763,000 -$222,000 -23% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $3,303,000 $699,000 -$11,000 -1.5% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2026 2025 FY
Q3 2024 $3,314,000 $734,000 -$129,000 -15% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $3,443,000 $885,000 +$9,000 +1% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $3,434,000 $985,000 +$129,000 +15% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $3,305,000 $710,000 -$357,000 -33% 01 Oct 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
Q3 2023 $3,662,000 $863,000 -$311,000 -26% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $3,973,000 $876,000 -$287,000 -25% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $4,260,000 $856,000 -$37,000 -4.1% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $4,297,000 $1,067,000 -$265,000 -20% 01 Oct 2022 31 Dec 2022 10-K 01 Mar 2024 2023 FY
Q3 2022 $4,562,000 $1,174,000 -$1,231,000 -51% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $5,793,000 $1,163,000 -$738,000 -39% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $6,531,000 $893,000 -$1,549,000 -63% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $8,080,000 $1,332,000 01 Oct 2021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
Q3 2021 $2,405,000 -$215,000 -8.2% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $1,901,000 -$8,867,000 -82% 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022 2022 Q2
Q1 2021 $2,442,000 +$683,000 +39% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q3 2020 $18,172,000 $2,620,000 +$1,351,000 +106% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $16,821,000 $10,768,000 +$9,380,000 +676% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $7,441,000 $1,759,000 +$740,000 +73% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $6,701,000 $3,025,000 +$4,887,000 01 Oct 2019 31 Dec 2019 10-K 03 Mar 2020 2019 FY
Q3 2019 $1,814,000 $1,269,000 +$275,000 +28% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $1,539,000 $1,388,000 +$642,000 +86% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $897,000 $1,019,000 +$197,000 +24% 01 Jan 2019 31 Mar 2019 10-Q 02 May 2019 2019 Q1
Q4 2018 $700,000 $1,862,000 -$2,097,000 -892% 01 Oct 2018 31 Dec 2018 10-K 04 Mar 2021 2020 FY
Q3 2018 $2,797,000 $994,000 +$405,000 +69% 01 Jul 2018 30 Sep 2018 10-Q 31 Oct 2019 2019 Q3
Q2 2018 $2,392,000 $746,000 +$434,000 +139% 01 Apr 2018 30 Jun 2018 10-Q 01 Aug 2019 2019 Q2
Q1 2018 $1,958,000 $822,000 +$506,000 +160% 01 Jan 2018 31 Mar 2018 10-Q 02 May 2019 2019 Q1
Q4 2017 $1,452,000 $235,000 01 Oct 2017 31 Dec 2017 10-K 03 Mar 2020 2019 FY
Q3 2017 $589,000 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2018 Q3
Q2 2017 $312,000 01 Apr 2017 30 Jun 2017 10-Q 01 Aug 2018 2018 Q2
Q1 2017 $316,000 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.